GE Healthcare AS Medical Diagnostics Norway

1. GE Healthcare ASMedical Diagnostics Norway Who are we today? What are our success criteria?

2. Energy Infrastructure Technology Infrastructure GECapital NBCUniversal Commercial Finance Healthcare Energy Aviation Water GE Money Transportation Corporate Treasury Oil & Gas Enterprise Solutions Who we are: GE business segments GE is Imagination at Work - a diversified technology, media and financial services company focused on solving some of the world's toughest problems. With products and services ranging from aircraft engines, power generation, water processing and security technology to medical imaging, business and consumer financing, media content and industrial products, we serve customers in more than 100 countries and employ more than 320,000 people worldwide.

3. Life Sciences Broad-based Diagnostics Information Technology Diagnostic imaging &Surgery Integrated admin. & clinical Discovery tools Medical Diagnostics Electronic medical records Protein & cell sciences Picture Archiving System (PACS) Clinical tissue biomarkers ClinicalSystems Broad solutions for healthcare

4. GE Healthcare • $17B global business unit of GE • $1B+/year in R&D investment • Over 2,000 research scientists • Nearly 1,000 PhDs • Multiple disciplines • 45 different nationalities • 44.000 employees

5. Medical Diagnostics (~4500 employees) • The only Pharmaceutical unit in GE • World leader in contrast agents and nuclear medicine products for diagnostic imaging across all modalities.

6. GE Healthcare AS – Norwegian branch of Medical DiagnosticsMilestones Pharmacist Morten Nyegaard Founder of Nyegaard & Co, later Nycomed, in 1874 Nycomed develops world’s first non-ionic X-ray contrast medium in collaboration with Professor Torsten Almén of Lund, Sweden Nycomed’s first X-ray contrast medium, a copy prep. reg.1934 Omnipaque, 2nd generation non-ionic X-ray contrast medium, for many years ranked among the top 10 pharma- ceutical products sold world-wide. The exceptional R&D environment that has emerged in Norway since 1874 will continue to play an important role in the development of new products for diagnosis, treatment and prevention of disease. This position was continued with the merger between Nycomed and Amersham International in 1997 - further strengthened under GE Healthcare from 2004

7. GE Healthcare AS Oslo site (Sec. manuf., R&D, 650 employees) Lindesnes site (Primary manuf. 350 employees) • Total revenues (incl exports): $ 1,0 billion • In market sales: $15,5 million • R&D 55 $ (ex 5.11) 136’ $ (08’) ( approx. 1 mill $ 09’) • approx. 200 employees • GEHC total no of employees: 1300 - Largest Pharma player in Norway

8. Key promoted brands Product Description ~ Annual Rev $m Launched 1993 ONLY Iso-Osmolar media All disease areas >500m Launched 1982 Global Gold standard All disease areas >700m Launched 1996 Myocardial perfusion >300m Launched 1993 Non-ionic MRI All disease areas >180m Launched 2000 First agent to identify Parkinson’s Disease >40m

9. So what’s makes a success? (I) • Key competences – focus • Decisiveness (privately owned at the time) • Available funding • The right product area – niche(?) • The right product opportunity - IPR • Key competence - develop

10. So what’s makes a success? (II) • Right strategy (build from strength) • Leverage partnerships (Schering/Daiichi/Sterling) & local strength • Transition to own presence (Schering-Sterling) • Focus on core competencies (CM…) • Continuous improvements (Lindesnes/primary production – retain competitiveness) • Long term R&D strategy and continuous investments (build capacity + feed pipeline) • Business Dvlp – M&A X

11. The Future … Molecular Medicine Pinpoint Detect Predict Prevent/Treat Imaging Protein In Vitro (IVD) Gene Assay Track and Verify Imaging, IVD MolecularDiagnostics MolecularImaging MolecularTherapeutics MolecularDiagnostics MolecularImaging MolecularTherapeutics Predict & Prevent Disease …

12. Molecular Medicine • Diagnose and treat before symptoms appear • Provide treatments tailored to individual’s genetic makeup • Focusing on cancer, heart disease and Alzheimer's • Collaborating with leading pharmaceutical companies and medical researchers • GE in best position to grow and leverage

13. Portfolio spans modalities and diseases Contrast Media Molecular Imaging Anatomy Function Perfusion Viability Metabolism X-Ray/CT MRI Optical Imaging SPECT TargetedSPECT PET Cardiology Oncology Neurology Urology

14. Post GE – why Norway? • Focus on core competencies (CM + MI) feed product pipeline • Continuous improvements (Lindesnes/primary production – maintain competitiveness) • Available competence – limitations Norway • Available funding  need competitive environment (R&D/technology developments: incentives) – global competition • Norway need to stay competitive – do’s & don’ts: • Cost levels  invest in high tech/focus on cost drivers • Funding  develop incentives – establish competitive advantages – commercialization is key • Competence  education + “brain” import simplification • Do not create obstacles  harmonized rules & regulations

15. Takk! Spørsmål?

16. What is Pharma? • $650B global market • $500MM - $1B sales per year • Highly regulated industry from development through marketing • General patent life ~ 20 yrs • Average drug development 10 – 15 yrs at a cost of greater than $1B* • Generally thought of as encompassing therapeutic drugs, both branded and generic • Chronic administration Therapeutics Diagnostics • $7B global market • Sub-segment of the pharmaceutical industry (“specialty pharma”) • $50 - $200MM sales per year • Drugs used to aid in diagnostic imaging procedures that highlight organs, tissues and processes in the body • Acute administration • Only 2 products approved in past 10 years • POS ranges from 16% phase 1 to 50% phase 3 *Includes costs of failed compounds

17. Fra Nyegaard & Co til GE Healthcare • 1874 Morten Nyegaard, cand pharm • 1890 Nyegaard & Co (Nyco) • 1986 Nycomed AS • 1992 Nycomed Imaging AS • 1997 Nycomed Amersham Imaging AS • Amersham Health AS • 2004 GE Healthcare